Inclusion body myositis with early onset: a population-based study

Area of Science:

• Neurology
• Genetics
• Pathology

Background:

• Inclusion body myositis (IBM) typically affects individuals over 45, with limited research on younger patients.
• IBM is an inflammatory myopathy causing progressive muscle weakness and lacks effective treatments.

Purpose of the Study:

• To characterize early-onset inclusion body myositis (IBM) in a population-based cohort.
• To investigate the clinical presentation, genetic factors, and survival outcomes in young IBM patients.

Main Methods:

• A 33-year population-based study identified 142 IBM patients, including six with early-onset IBM (onset <50 years).
• Data collected included medical records, muscle strength, comorbidities, muscle biopsies, and nuclear/mitochondrial DNA.
• Early-onset IBM cases were compared with age-matched IBM patients and controls.

Main Results:

• The median age at symptom onset for early-onset IBM was 36 years; diagnosis occurred at a median of 43 years.
• Median survival from diagnosis was 14 years, with a prevalence of 1.2 per million inhabitants.
• Significant quadriceps muscle strength decline (0.91%/month) and high mitochondrial DNA mutation load were observed.

Conclusions:

• Early-onset IBM is a severe, progressive myopathy in young and middle-aged individuals.
• The disease is associated with significant muscle weakness, mitochondrial dysfunction, and reduced survival.
• Further research is needed to understand the underlying mechanisms and develop treatments for early-onset IBM.